TY  - JOUR
T1  - Cetuximab-Related Skin Toxicity as a Predictive Marker for Treatment Response and Prognosis in Recurrent/Metastatic Head and Neck Cancer Patients Treated with Cetuximab and Chemotherapy Combination
TT  - Setüksimab ve Kemoterapi Kombinasyonu ile Tedavi Edilen Rekürren/Metastatik Baş ve Boyun Kanserli Hastalarda Tedavi Yanıtı ve Prognoz İçin Prediktif Bir Belirteç Olarak Setüksimab İlişkili Cilt Toksisitesi
AU  - Çitakkul, İlkay
AU  - Uygun, Kazım
AU  - Bakkal Temi, Yasemin
AU  - Özden, Ercan
AU  - Kefeli, Umut
AU  - Çabuk, Devrim
AU  - Sahin, Elif
PY  - 2025
DA  - June
Y2  - 2025
DO  - 10.53446/actamednicomedia.1640000
JF  - Acta Medica Nicomedia
JO  - Acta Med Nicomedia
PB  - Kocaeli Üniversitesi
WT  - DergiPark
SN  - 2717-8994
SP  - 164
EP  - 168
VL  - 8
IS  - 2
LA  - en
AB  - AbstractObjective: Cetuximab (Cmab)-related skin toxicity is a frequent adverse reaction in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (r/mSCCHN). We wanted to evaluate whether skin toxicity can be used as a prognostic marker for the treatment of patients who are receiving Cmab therapy for r/mSCCHN.Methods: A retrospective review was conducted of demographic data, prognostic features, treatment responses, Cmab-related skin toxicity, and dates of diagnosis, treatment initiation, progression, and death for r/mSCCHN patients treated with Cmab at Kocaeli University Medical Oncology Department between 2010 and 2019.Significance of the results has been evaluated by using SPSS (20.0 SPSS Inc., Chicago, IL, USA.) statistical program.Results: A total of 77 patients were enrolled.A significant association was found between Cmab-related skin toxicity and longer survival in patients with r/mSCCHN. Patients without skin toxicity had shorter progression-free survival (PFS) compared to those with grade 1 and grade 2 skin toxicity. Notably, patients who had grade 3 skin toxicity exhibited longer overall survival (OS) and significantly better PFS than those without skin toxicity, as well as those with grade 1 or grade 2 toxicity. No significant OS difference was observed between patients with grade 1 or grade 2 toxicity and those without skin toxicity.Conclusions: Skin toxicity, particularly grade 3, is associated with improved prognosis, with longer OS and PFS. Grade 1 and grade 2 skin toxicity are linked to better PFS compared to no toxicity. These findings suggest that preventive strategies to manage Cmab-related skin toxicity, especially grade 2 and grade 3, may enhance patient outcomes.
KW  - cetuximab
KW  - head and neck cancer
KW  - skin toxicity
N2  - ÖzAmaç: Rekürren veya metastatik baş ve boyun kanserinde(r/mSCCHN)  Setuximab (Cmab) ile ilişkili cilt toksisitesi, tedavide sık görülen bir yan etkidir. Cilt toksisitesinin prognostik bir ölçüt olarak kullanılıp kullanılamayacağını değerlendirmek istedik. Yöntem: 2010-2019 yılları arasında Kocaeli Üniversitesi Tıbbi Onkoloji Bölümü'nde Cmab ile tedavi edilen r/mSCCHN hastalarının demografik verileri, prognostik özellikleri, tedavi yanıtları, Cmab ile ilişkili cilt toksisitesi, tanı zamanı, tedavi başlama zamanı, progresyon ve ölüm tarihleri retrospektif olarak incelenmiş ve sonuçların anlamlılığı SPSS (20.0 SPSS Inc., Chicago, IL, USA.) istatistik programı kullanılarak değerlendirilmiştir.Bulgular: Toplam 77 hasta çalışmaya dahil edilmiştir.R/M SCCHN hastalarında Cmab ile ilişkili cilt toksisitesi ile daha uzun sağkalım arasında anlamlı bir ilişki bulunmuştur. Cilt toksisitesi olmayan hastalarda, grad 1 ve grad 2 cilt toksisitesi olanlara kıyasla daha kısa progresyonsuz sağkalım (PFS) görülmüştür. Özellikle, grad 3 cilt toksisitesi olan hastalar, cilt toksisitesi olmayanların yanı sıra grad 1 veya grad 2 toksisitesi olanlara göre daha uzun genel sağkalım (OS) ve daha iyi PFS sergilemiştir. Grad 1 veya grad 2 toksisitesi olan hastalar ile cilt toksisitesi olmayan hastalar arasında anlamlı bir OS farkı gözlenmemiştir.Sonuç: Özellikle grad 3 cilt toksisitesi , daha uzun OS ve PFS ile yani daha iyi prognoz ile ilişkilidir. Grad 1 ve grad 2 cilt toksisitesi, cilt toksisitesi olmayanlara kıyasla daha iyi PFS ile bağlantılıdır. Bu bulgular, Cmab ile ilişkili cilt toksisitesini, özellikle de grad 2 ve grad 3 cilt toksisitesini yönetmeye yönelik önleyici stratejilerin hasta sonuçlarını iyileştirebileceğini göstermektedir.
CR  - Marur S, Forastiere AA. Head and Neck Cancer: Changing Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2008;83(4):489-501. doi:10.4065/83.4.489
CR  - Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5). doi:10.1002/ijc.29210
CR  - Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5(6):521-526. doi:10.1093/OXFORDJOURNALS.ANNONC.A058906
CR  - Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562-3567. doi:10.1200/JCO.2005.01.057
CR  - Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257-263. doi:10.1200/JCO.1992.10.2.257
CR  - Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10(8):1245-1251. doi:10.1200/JCO.1992.10.8.1245
CR  - Guigay J, Aupérin A, Fayette J, et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-475. doi:10.1016/S1470-2045(20)30755-5
CR  - Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. New England Journal of Medicine. 2008;359(11):1116-1127. doi:10.1056/NEJMOA0802656/ASSET/A666E058-0210-4F26-B697-A012FB7B4135/ASSETS/IMAGES/LARGE/NEJMOA0802656_T3.JPG
CR  - Common Terminology Criteria for Adverse Events (CTCAE) | Protocol Development | CTEP. Accessed January 6, 2025. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40
CR  - Uozumi S, Enokida T, Suzuki S, et al. Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. Front Oncol. 2018;8. doi:10.3389/fonc.2018.00616
CR  - Pinto C, Barone CA, Girolomoni G, et al. Management of Skin Toxicity Associated with Cetuximab Treatment in Combination with Chemotherapy or Radiotherapy. Oncologist. 2011;16(2):228-238. doi:10.1634/theoncologist.2010-0298
CR  - Salas S, Baumstarck-Barrau K, Alfonsi M, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial. Radiother Oncol. 2009;93(3):503-509. doi:10.1016/J.RADONC.2009.05.016
CR  - Lee JH, Machtay M, Unger LD, et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124(8):871-875. doi:10.1001/ARCHOTOL.124.8.871
UR  - https://doi.org/10.53446/actamednicomedia.1640000
L1  - https://dergipark.org.tr/tr/download/article-file/4610199
ER  -